Koya Medical

High-Level Overview

Koya Medical is a medtech company developing wearable active compression therapies for lymphedema and venous disorders, with its flagship Dayspring system enabling patient mobility during treatment.[1][2][3] Founded in 2018, it serves patients with chronic edema and healthcare providers, addressing limitations of traditional pneumatic compression by offering nonpneumatic, app-controlled devices that support daily activities and improve adherence.[2][3][4] The company has shown strong growth, raising $26M in Series B funding in 2022 to expand commercialization, publishing clinical data like the NILE trial, securing FDA clearances and CMS billing codes, and opening a 35,000 sq ft Dallas HQ in 2025 to scale manufacturing amid rising demand.[1][2][3][4]

Origin Story

Koya Medical was founded in 2018 by Andy Doraiswamy, Ph.D., who serves as president and CEO, inspired by a personal journey with post-cancer lymphedema that highlighted gaps in existing treatments.[2][3] Doraiswamy's background in transformative healthcare drove the creation of patient-centric platforms starting with the Dayspring system, initially FDA-cleared for upper extremities in 2020 and lower extremities in 2021, followed by U.S. commercial launch.[1][2] Early traction included CMS billing codes in 2022 and $26M Series B funding to accelerate expansion, with pivotal moments like the NILE head-to-head clinical trial validating efficacy over legacy devices.[2][4] The company evolved from an Oakland R&D hub to a Dallas-based HQ in 2025, reflecting revenue-driven scaling.[3][6]

Core Differentiators

Koya Medical stands out in vascular health through these key features:

• Mobility-Enabled Design: Dayspring is the first nonpneumatic, wearable active compression system FDA-cleared for lymphedema and venous conditions, using Flexframe technology for spring-like segments in breathable mesh garments that allow natural movement unlike stationary pneumatic devices.[1][2][3][4]
• Personalized Tech Integration: Includes a Bluetooth-enabled, rechargeable controller and companion app for customizing treatments, tracking history, and clinician oversight, boosting adherence and quality of life.[1][2][4]
• Clinical Validation: Backed by multi-center trials like NILE (published in Journal of Vascular Surgery), showing edema reduction, satisfaction gains, and superiority in mobility.[4]
• Scalable Operations: Vertically integrated manufacturing, with a new Dallas HQ for production and a Silicon Valley R&D hub, supporting rapid commercialization and pipeline expansion.[3][6]

Role in the Broader Tech Landscape

Koya Medical rides the wave of home-based vascular care innovation, targeting the millions affected by lymphedema and venous diseases amid rising chronic condition prevalence and demand for patient-empowering medtech.[2][3][7] Timing aligns with post-pandemic shifts to ambulatory treatments, FDA/CMS support accelerating adoption, and medtech funding for mobility-focused devices.[1][2] Market forces like aging populations and lymphedema's lifelong needs favor non-invasive, adherent solutions over bulky alternatives, positioning Koya to influence lymphatic/venous care ecosystems through clinical evidence and comprehensive pipelines from clinic to home.[3][4][8] By redefining compression as wearable tech, it bridges gaps in vascular health, inspiring similar patient-centric medtech advancements.[7][9]

Quick Take & Future Outlook

Koya Medical's trajectory points to accelerated growth via Dayspring commercialization, pipeline expansions for new indications, and global scaling from its Dallas hub.[2][3] Trends like AI-personalized therapies, telehealth integration, and value-based care will shape its path, amplifying clinical outcomes and market penetration.[4][8][9] Its influence may evolve into a vascular health platform leader, potentially through partnerships or further funding, transforming lives for chronic edema patients as it began with a founder's personal story.[2][3]